Commonwealth Equity Services LLC lifted its stake in Crispr Therapeutics AG (NASDAQ:CRSP) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,201 shares of the company’s stock after acquiring an additional 386 shares during the period. Commonwealth Equity Services LLC’s holdings in Crispr Therapeutics were worth $746,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in CRSP. NEXT Financial Group Inc raised its stake in Crispr Therapeutics by 915.0% in the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares during the period. Benjamin Edwards Inc. boosted its stake in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after purchasing an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. acquired a new position in shares of Crispr Therapeutics during the 3rd quarter worth about $26,000. US Bancorp DE raised its position in shares of Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares during the last quarter. Finally, BSW Wealth Partners acquired a new stake in Crispr Therapeutics in the 2nd quarter valued at about $39,000. Hedge funds and other institutional investors own 49.81% of the company’s stock.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares in the company, valued at approximately $412,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 over the last quarter. 21.40% of the stock is owned by insiders.

CRSP has been the subject of a number of research analyst reports. Oppenheimer increased their price objective on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Roth Capital increased their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. BidaskClub upgraded shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a report on Tuesday, November 19th. Two analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $69.54.

Shares of NASDAQ:CRSP opened at $71.65 on Monday. The stock has a market capitalization of $3.76 billion, a P/E ratio of -20.83 and a beta of 3.15. Crispr Therapeutics AG has a 1-year low of $22.22 and a 1-year high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $49.98 and a two-hundred day moving average price of $46.23.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. As a group, equities analysts predict that Crispr Therapeutics AG will post 0.65 EPS for the current year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: How to Invest in Marijuana Stocks

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link